Immatics: A Promising TCR Pipeline

Immatics (NASDAQ: IMTX ) is an early-stage biotech that focuses on cell-based immunotherapies, also known as Adoptive Cell Therapy (ACT), for solid cancers. I believe their stock is promising and is a buy(bullish) based on my analysis of their I graduated with an M.D from the University of Pavia, Italy. Soon after starting my clinical career I realized I was much more drawn towards statistics and analyzing clinical trials/research. Around that time I was also introduced to the world of Finance and realized ...